June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Freeze Drying to Develop a Bevacizumab-based Tablet for Ocular Implantation
Author Affiliations & Notes
  • Garima Sharma
    Pharmaceutics, UCL School of Pharmacy, London, United Kingdom
    National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Ashkan Khalili
    National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Sahar Awwad
    Pharmaceutics, UCL School of Pharmacy, London, United Kingdom
    National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Kiran Malik
    National Institute for Biological Standards and Control, Health Protection Agency, Potters Bar, United Kingdom
  • Paul Matejtschuk
    National Institute for Biological Standards and Control, Health Protection Agency, Potters Bar, United Kingdom
  • Simon Gaisford
    Pharmaceutics, UCL School of Pharmacy, London, United Kingdom
  • Steve Brocchini
    Pharmaceutics, UCL School of Pharmacy, London, United Kingdom
    National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Peng Khaw
    National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Footnotes
    Commercial Relationships Garima Sharma, None; Ashkan Khalili, University College London (P); Sahar Awwad, None; Kiran Malik, None; Paul Matejtschuk, None; Simon Gaisford, None; Steve Brocchini, None; Peng Khaw, University College Moorfields (P)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1082. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Garima Sharma, Ashkan Khalili, Sahar Awwad, Kiran Malik, Paul Matejtschuk, Simon Gaisford, Steve Brocchini, Peng Khaw; Freeze Drying to Develop a Bevacizumab-based Tablet for Ocular Implantation. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1082.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Bevacizumab has shown the potential to control scarring when administered into the subconjunctival space following glaucoma filtration surgery (GFS). To overcome the problem of rapid clearance, a solid dosage implantable tablet form of this antibody that provides prolonged release in the bleb is being developed. In an effort to optimise dose, we are examining each step used for tablet fabrication. As is often the case for any protein pharmaceutical presented in a solid reconstitutable form, a critical process step is lyophilisation, which can cause aggregation of the protein with loss of activity. The aim of this study is to characterise the lyophilisation of the bevacizumab formulation used to fabricate the subconjunctival implantable tablet. Determination of the glass transition temperature (Tg’) and collapse temperature (Tc) during lyophilisation assists in the development of a suitable freeze-drying cycle.

 
Methods
 

Differential Scanning Calorimetry (DSC) was used to measure the Tg’ of the excipients alone and in combination with the antibody. Freeze Drying Microscopy (FDM) was used to study the collapse temperature (Tc) for the excipients (trehalose and hyaluronic acid (HA)) and the formulation. The antibody formulation was characterised by size exclusion chromatography (SEC) and gel electrophoresis.

 
Results
 

DSC experiments indicate the sub-ambient glass transition temperature (Tg’) for bevacizumab to be -28.24°C (n=2) and that of trehalose to be -29.36°C (n=2). The melting endotherm of HA was -23.71°C (n=2) as no Tg’ could be observed. This can be attributed to the presence of buffer salts present in the HA formulation leading to a eutectic melt. FDM was used to monitor the progress of lyophilisation to determine the collapse temperature of the formulation (Fig. 1). The collapse temperature of the pharmaceutical formulation of bevacizumab was found to be -36°C (n=2).

 
Conclusions
 

Freeze-drying is a suitable technique to obtain a solid form of antibody that can be fabricated as a tablet. Characterisation of freeze-drying using FDM and DSC suggested that starting the primary drying below -36 °C may avoid collapse of the cake during scale up for freeze drying of the bevacizumab formulation.

 
 
Fig. 1. Progression of freeze drying of bevacizumab formulation for tablet fabrication using FDM: A) Sample frozen at -60°C B) Sample drying at -40°C C) Sample drying with collapse at -35°C
 
Fig. 1. Progression of freeze drying of bevacizumab formulation for tablet fabrication using FDM: A) Sample frozen at -60°C B) Sample drying at -40°C C) Sample drying with collapse at -35°C
 
Keywords: 658 protein purification and characterization • 765 wound healing  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×